RxDoctor Payments Data

John Selle, DO

Internal Medicine · San Francisco, CANPI 1518950351

Payments from drug & device makers

$365in general payments, 2019–2025

Across 16 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$89
  • Pfizer$73
  • AbbVie$66
  • GSK$43
  • Lilly USA, LLC$35
  • Dexcom, Inc.$24
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$33090%
  • Education$3510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$146,283
Medicare patients
356
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$84,927
JardianceEmpagliflozin66$57,550
OzempicSemaglutide45$49,695
JanuviaSitagliptin Phosphate38$48,775
TradjentaLinagliptin21$14,711
MyrbetriqMirabegron15$12,195
BelsomraSuvorexant17$7,766
FarxigaDapagliflozin Propanediol12$7,349
MovantikNaloxegol Oxalate15$5,904
Breo ElliptaFluticasone/Vilanterol13$4,917
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$4,836
Levothyroxine Sodium241$3,466
Atorvastatin Calcium356$3,171
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$2,734
Wixela InhubFluticasone Propion/Salmeterol30$2,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$84,92797 claims
GSKBreo Ellipta$43$4,91713 claims
AbbVieSynthroid$66$1,14913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →